John Marlin Storring

Dr. Storring trained in internal medicine at the Jewish General Hospital and in hematology at the McGill University Health Centre (MUHC) before completing a fellowship in acute leukemia and cellular therapy at Princess Margaret Hospital in Toronto. He became a member of the MUHC’s Department of Medicine, Division of Hematology in 2007, where he cares for patients with both benign and malignant hematologic disorders. He is part of the stem cell transplant group at the Royal Victoria Hospital and is an Assistant Professor in McGill’s Department of Hematology.

Since arriving at the MUHC, he began a dedicated clinic in myelodysplasia and acute myeloid leukemia. In collaboration with other experts, he helped develop pan-Canadian evidence-based treatment guidelines for use in patients with myelodysplastic syndrome and acute leukemia. Dr. Storring is also the principle investigator for several clinical trials in acute leukemia and myelodysplasia with a focus on the development of novel compounds that may have enhanced efficacy coupled with a favourable toxicity profile.

His research focuses on the treatment of bone marrow cancers, in particular the leukemias and myelodysplastic syndrome. He is the local lead investigator on several national and international studies in hematologic malignancy. Additionally, in conjunction with other Canadian centres he is building a registry of patients with myelodysplastic syndrome that will offer insights into how these patients are managed in Canada, the outcomes of their treatments and their quality of life.